Bob Laverty

Former Media Contact Relations at The Medicines Co.

Bob Laverty

Bob Laverty

Former Media Contact Relations at The Medicines Co.

Biography

Bob Laverty is former Vice President-Communications at The Medicines Co.

Overview
RelSci Relationships

139

Contact Data
Trying to get in touch with Bob Laverty? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Bob Laverty likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Senior Director-Global Distribution at The Medicines Co.

Relationship likelihood: Average

Chief Development Officer at Matinas BioPharma Holdings, Inc.

Relationship likelihood: Average

Chief Financial Officer, Treasurer & Senior Vice President at IVERIC bio, Inc.

Relationship likelihood: Average

Affiliate Scholar in Residence at Georgetown University

Relationship likelihood: Average

Chief Executive Officer at Caldera Health Ltd.

Relationship likelihood: Average

Chief Executive Officer & President at IVERIC bio, Inc.

Relationship likelihood: Average

Head, Global Communications at The Medicines Co.

Relationship likelihood: Average

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Relationship likelihood: Average

Vice President-New Business Ventures at The Medicines Co.

Relationship likelihood: Average

Former Vice President & General Manager-Mergers & Acquisitions at The Medicines Co.

Relationship likelihood: Average

Paths to Bob Laverty
Potential Connections via
Relationship Science
You
Bob Laverty
Former Media Contact Relations at The Medicines Co.
Career History
Media Contact Relations
Prior - 2016

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Other Affiliations

Bob Laverty is affiliated with The Medicines Co.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bob Laverty. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bob Laverty's profile does not indicate a business or promotional relationship of any kind between RelSci and Bob Laverty.